Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis Q1 Earnings Call Highlights
Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.81 per share a year ago.
Enovis (ENOV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock
Enovis (ENOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript
Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript
Enovis (ENOV) Q4 Earnings Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.98 per share a year ago.
Enovis: Valuation Is Too Low, But Needs To Differentiate On Growth
Enovis continues to struggle in the market, as institutional investors just aren't interested in mid-single-digit growth from a mid-cap name. Management has guided for up to low-double-digit Recon growth in 2026, but overall growth, margin leverage, and meaningful free cash flow generation remain key hurdles for rerating. Bringing successful products over from Europe could drive more growth in hips and shoulders, but it will take time and clinical trials to get them to the market.
Enovis Corporation (ENOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Enovis Corporation (ENOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Enovis Corporation (ENOV) Presents at UBS Global Healthcare Conference 2025 Transcript
Enovis Corporation ( ENOV ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good afternoon, everyone.
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.73 per share a year ago.
